Bristol Myers Squibb seals $380M CAR-T therapy production deal
With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable
Stay updated with breaking news from Cellare Cell Shuttle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
With equipment that promises to produce 10 times more therapies, the deal with Cellares is hoped to make BSM's CAR-T ambitions more scalable and affordable
908 Devices Inc. , a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and Cellares, the first Integrated Development and Manufacturing Organization ...
Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-...
/PRNewswire/ -- Cellares Corporation, a life sciences technology company pioneering a revolutionary automated approach to cell therapy manufacturing, today...